PhaseV, a leader in AI/ML-driven clinical development, today announced the completion of a $50 million Series A funding round. Co-led by Accel and Insight Partners and with participation of existing ...

PhaseV Inc. raised $50 million in a series A funding round to further develop its machine learning (ML) platform which helps companies reduce the cost and duration of clinical trials, and increase ...

About PhaseV PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive ...

BOSTON, Sept. 12, 2024 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today the latest capabilities of its AdaptV platform to ...

BOSTON, April 8, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced its participation in several upcoming biotech and data science conferences. The company ...

Moderated by Brad Carlin PhD, Senior Director, Data Science and Statistics at PhaseV, the panel will discuss: AI-driven approaches for smarter patient selection to optimize recruitment and site ...